Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2025 07:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea’s PAS-004 shows superior ETS2 inhibition vs. selumetinib, highlighting promise as a new treatment for IBD and other inflammatory diseases.
March 27, 2025 15:38 ET | Source: Spherix Global Insights

US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights

EXTON, PA, March 27, 2025 (GLOBE NEWSWIRE) -- In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu...
March 03, 2025 13:00 ET | Source: DelveInsight Business Research LLP

JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight |...
December 19, 2023 08:00 ET | Source: Biora Therapeutics, Inc.

Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform

Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
February 11, 2020 16:00 ET | Source: Reports and Data

Ankylosing Spondylitis Drugs Market To Reach USD 8.82 Billion By 2027 | Reports And Data

New York, Feb. 11, 2020 (GLOBE NEWSWIRE) -- The global ankylosing spondylitis drugs market is forecast to reach USD 8.82 Billion by 2027, according to a new report by Reports and Data. Ankylosing...
June 30, 2009 09:51 ET | Source: Cutting Edge Information

Biologics Dominate the Autoimmune Market but Small Molecules Still Have Some Fight Left, Says Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwire - June 30, 2009) - Biological drugs are the big winners in the market for autoimmune disorders. According to "Autoimmune Market Forecast to 2014," the latest...